ICP-538
/ InnoCare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 08, 2026
InnoCare Pharma…announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials of ICP-538, a VAV1-directed molecular glue degrader (MGD)
(GlobeNewswire)
- "This is the first VAV1 degrader approved to enter clinical trials in China and the second globally. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors, for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis."
New trial • Inflammatory Bowel Disease • Multiple Sclerosis • Systemic Lupus Erythematosus
1 to 1
Of
1
Go to page
1